Louisiana 2020 2nd Special Session

Louisiana Senate Bill SB60

Introduced
10/6/20  
Introduced
10/6/20  
Refer
10/6/20  

Caption

Provides relative to opioid prescriptions. (gov sig) (Item #28)

Impact

The legislative intent behind SB60 is to promote public health by ensuring that medical practitioners consistently review patients' prescription histories before prescribing opioids. This change seeks to reduce abuse and addiction rates associated with opioids, which have significantly increased in Louisiana and nationwide. By requiring prescribers to access the PMP regardless of the duration of the prescription, the bill aims to foster a more vigilant approach to opioid prescribing, potentially affecting the practices of healthcare providers across the state.

Summary

SB60 aims to address the ongoing opioid crisis in Louisiana by mandating stricter oversight of opioid prescriptions. Specifically, it amends the existing prescription monitoring program (PMP) regulations by removing exceptions that previously allowed prescribers to bypass the requirement of accessing the PMP when prescribing short-term opioid prescriptions of no more than seven days. The bill reflects the state's commitment to mitigating the risks associated with opioid misuse and enhancing public health initiatives.

Sentiment

Opinions on SB60 are expected to be mixed among stakeholders. Supporters, particularly public health advocates, view the bill as a critical step towards combating the opioid epidemic, emphasizing the need for continuous monitoring of prescriptions to prevent misuse. Conversely, some healthcare providers may express concern regarding the added burdensome requirements that this legislation places on their prescribing practices, suggesting a need for balance between oversight and medical autonomy.

Contention

One significant point of contention surrounding SB60 involves the balance between patient safety and the potential bureaucratic burden on prescribers. While the bill addresses a pressing public health crisis, opponents might argue that requiring access to the PMP for every opioid prescription could hinder timely patient care. Additionally, stakeholders will need to carefully consider how the new requirements affect the treatment of patients who may require immediate pain relief without unnecessary delays.

Companion Bills

No companion bills found.

Similar Bills

CA AB149

Controlled substances: prescriptions.

TX HB2766

Relating to electronic and other controlled substance prescriptions under the Texas Controlled Substances Act; authorizing a fee.

CA AB2789

Health care practitioners: prescriptions: electronic data transmission.

CA AB1353

Health care coverage: prescription drugs: continuity of care.

TX HB2174

Relating to controlled substance prescriptions and reimbursement for treatment for certain substance use disorders; authorizing a fee.

TX SB1233

Relating to controlled substance prescriptions under the Texas Controlled Substances Act; authorizing a fee.

CA AB1998

Opioids: safe prescribing policy.

TX HB2246

Relating to certain procedures applicable to electronic prescriptions for Schedule II controlled substances.